US2021309615A1PendingUtilityA1

Phenyl amino pyrimidine compounds and uses thereof

54
Assignee: YM BIOSCIENCES AUSTRALIA PTY LTD C/O GILEAD SCIENCES INCPriority: Mar 12, 2007Filed: Dec 7, 2015Published: Oct 7, 2021
Est. expiryMar 12, 2027(~0.6 yrs left)· nominal 20-yr term from priority
Inventors:Christopher J. BurnsAndrew Craig DonohueJohn Thomas FeutrillThao Lien Thi NguyenAndrew Frederick WilksJun Zeng
A61P 35/00A61P 35/02A61K 31/5377A61P 17/00A61P 3/06C07D 403/12A61P 37/08A61P 43/00C07D 413/12A61P 1/00A61P 17/04C07D 295/02A61P 17/10A61P 19/02C07D 295/12A61P 9/00C07D 417/12A61P 7/00A61P 5/00A61P 1/18C07D 405/12C07D 401/12A61P 37/06A61P 25/28A61P 37/00C07D 239/42A61P 31/12A61P 1/04A61P 21/00A61P 19/06A61P 37/02A61P 3/00A61P 19/00A61P 9/04A61P 11/00A61P 3/10C07D 401/14A61P 9/12A61K 31/506A61P 17/06A61P 25/06A61P 31/00A61P 31/04A61P 9/10A61P 11/02A61P 9/08A61P 29/00A61P 25/00A61P 11/08A61P 7/02A61P 13/12A61P 1/16A61P 11/06
54
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention relates to phenyl amino pyrimidine compounds which are inhibitors of protein kinases including JAK kinases. In particular the compounds are selective for JAK2 kinases. The kinase inhibitors can be used in the treatment of kinase associated diseases such as immunological and inflammatory diseases including organ transplants; hyperproliferative diseases including cancer and myeloproliferative diseases; viral diseases; metabolic diseases; and vascular diseases.

Claims

exact text as granted — not AI-modified
1 - 23 . (canceled) 
     
     
         24 . A method of treating a hyperproliferative disorder comprising administering to a patient in need thereof a compound of the formula: 
       
         
           
           
               
               
           
         
         or a pharmaceutically acceptable salt thereof. 
       
     
     
         25 . The method of  claim 24 , wherein the hyperproliferative disorder is cancer. 
     
     
         26 . The method of  claim 24 , wherein the hyperproliferative disorder is acute myelogenous leukemia. 
     
     
         27 . The method of  claim 24 , wherein the hyperproliferative disorder is acute lymphocytic leukemia. 
     
     
         28 . The method of  claim 24 , wherein the hyperproliferative disorder is glioma.

Join the waitlist — get patent alerts

Track US2021309615A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.